Derek C. H. Chan

Derek C. H. Chan

Auto-generated profile, based on publicly available information

Derek C. H. Chan

Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2023 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
AVAna Vujovic
Ana Vujovic
LRLaura de Rooij
Laura de Rooij
ACAva Keyvani Chahi
Ava Keyvani Chahi
HCHe Tian Chen
He Tian Chen
BYBrian A. Yee
Brian A. Yee
KHKristin J. Hope
Kristin J. Hope
Acute myeloid leukemia (AML) is fueled by leukemic stem cells (LSC) whose determinants are challenging to discern from hematopoietic stem cells (HSC) or uncover by approaches focused on general cell properties. We have identified a set of RNA-binding proteins (RBP) selectively enriched in human AML LSCs. Using an in vivo two-step CRISPR-Cas9 screen to assay stem cell functionality, we found 32 RBPs essential for LSCs in MLL-AF9;NrasG12D AML. Loss-of-function approaches targeting key hit RBP ELAVL1 compromised LSC-driven in vivo leukemic reconstitution, and selectively depleted primitive malignant versus healthy cells. Integrative multiomics revealed differentiation, splicing, and mitochondrial metabolism as key features defining the leukemic ELAVL1–mRNA interactome with mitochondrial import protein, TOMM34, being a direct ELAVL1-stabilized target whose repression impairs AML propagation. Altogether, using a stem cell–adapted in vivo CRISPR screen, this work demonstrates pervasive reliance on RBPs as regulators of LSCs and highlights their potential as therapeutic targets in AML. Significance: LSC-targeted therapies remain a significant unmet need in AML. We developed a stem-cell–adapted in vivo CRISPR screen to identify key LSC drivers. We uncover widespread RNA-binding protein dependencies in LSCs, including ELAVL1, which we identify as a novel therapeutic vulnerability through its regulation of mitochondrial metabolism. This article is highlighted in the In This Issue feature, p. 171

18 August 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
DCDerek C. H. Chan
Derek C. H. Chan
JXJoshua Xu
Joshua Xu
AVAna Vujovic
Ana Vujovic
NWNicholas Wong
Nicholas Wong
VGVictor Gordon
Victor Gordon
KHKristin J. Hope
Kristin J. Hope
How hematopoietic stem cells (HSCs) coordinate their divisional axis and whether this orientation is important for stem cell–driven hematopoiesis is poorly understood. Single-cell RNA sequencing data from patients with Shwachman-Diamond syndrome (SDS), an inherited bone marrow failure syndrome, show that ARHGEF2, a RhoA-specific guanine nucleotide exchange factor and determinant of mitotic spindle orientation, is specifically downregulated in SDS hematopoietic stem and progenitor cells (HSPCs). We demonstrate that transplanted Arhgef2−/− fetal liver and bone marrow cells yield impaired hematopoietic recovery and a production deficit from long-term HSCs, phenotypes that are not the result of differences in numbers of transplanted HSCs, their cell cycle status, level of apoptosis, progenitor output, or homing ability. Notably, these defects are functionally restored in vivo by overexpression of ARHGEF2 or its downstream activated RHOA GTPase. By using live imaging of dividing HSPCs, we show an increased frequency of misoriented divisions in the absence of Arhgef2. ARHGEF2 knockdown in human HSCs also impairs their ability to regenerate hematopoiesis, culminating in significantly smaller xenografts. Together, these data demonstrate a conserved role for Arhgef2 in orienting HSPC division and suggest that HSCs may divide in certain orientations to establish hematopoiesis, the loss of which could contribute to HSC dysfunction in bone marrow failure.

6 July 2022 in medRxiv
Verified
Preprint
Open access
PDF file
DCDerek C. H. Chan
Derek C. H. Chan
FKFiona G. Kouyoumdjian
Fiona G. Kouyoumdjian
APAndrea J. Pang
Andrea J. Pang
YNYue Niu
Yue Niu
UAUma H. Athale
Uma H. Athale
MVMadeleine M. Verhovsek
Madeleine M. Verhovsek
Importance: Acute vaso-occlusive crisis (VOC) in sickle cell disease (SCD) often leads patients to seek emergency department (ED) care. The landscape of SCD ED care within Canada’s universal and publicly funded healthcare system remains largely undefined. Objective: To characterize the quality of SCD VOC ED and inpatient care in Ontario, Canada. Design, Setting and Participants: We used population-level health administrative data to identify patients with SCD in Ontario, Canada who presented to the ED with SCD VOC (ICD-10-CA code D57.0) from 2006 to 2018. We derived two reference patient cohorts from the general population and separately from a validated Crohn’s disease cohort matched at the level of ED visits by age, sex, neighbourhood income quintile, geography, date range of visit, and ED triage score. Main Outcomes and Measures: Quality of care metrics included the number of ED visits, triage scores, time to physician initial assessment, time from triage to disposition, type of disposition, number of hospital admissions, length of admission for those admitted to hospital, number of repeat ED visits within a 14- and 30-day time window, and number of ED visits within any 1-year period. Stratifying variables and sociodemographic data included the month and year of ED visit, age bracket, triage scores, sex, rurality, Ontario’s marginalization indices (neighbourhood income, dependency, deprivation, ethnic concentration, instability), and number of ED visits within any 1-year period. Results: We identified 2,123 patients who presented to the ED with SCD VOC for a total of 18,712 unscheduled ED visits. Annual ED visit rates ranged from a mean of 2.6 to 14.2 visits per patient, with 4.6% of patients having incurred 38.4% of all SCD VOC ED visits. Subgroup analyses showed that adult patients with SCD VOC visited the ED 2.5 times more than pediatric patients, but their wait times for initial physician assessment were significantly longer (90.6 vs. 51.1 minutes, p < 0.0001) with a difference that was disproportionately larger than the reference cohorts. Males with SCD VOC experienced significantly shorter ED and inpatient stays compared to females (e.g. admission length of stay: 4.4 vs. 5.8 days, p < 0.0001), but their ED return rates within 30-days were significantly higher (0.89 vs. 0.35 times, p < 0.0001) with a difference that was disproportionately larger relative to the reference cohorts. Lower-income neighbourhoods correlated with lower acuity triage scores for SCD VOC visits and increased repeat ED visit rates at more pronounced levels than the reference cohorts. Higher acuity triage scores for adults with SCD VOC correlated with improved metrics for quality of ED and inpatient care with fewer longer-term ED visits. Conclusions and Relevance: Patients with SCD VOC carry a significant burden of acute care needs, with a smaller patient subset whose high ED visit rates have distinctly increased over time in Ontario, Canada. Adults, males and those from lower income quintile neighbourhoods with SCD VOC experienced lower quality of care metrics compared to their counterparts, with differences that were disproportionately larger than those found in the general ED population and in patients with Crohn’s disease. Higher acuity ED triage scores reflected improved downstream quality of care metrics for adult patients with SCD VOC. Future work should address these identified care quality disparities for SCD VOC that remain present within a universal and publicly funded healthcare system. Key Points: Question: What is the quality of emergency department (ED) and inpatient care for patients with sickle cell disease (SCD) vaso-occlusive crisis (VOC) in Ontario, Canada? Findings: This population-based matched cohort study of 2,123 patients with 18,712 ED visits for SCD VOC identified that adults, males and those from lower-income neighbourhoods experienced lower quality of care metrics compared to their counterparts, with differences that were disproportionately larger than those in two reference patient cohorts. Meaning: Disparities in the quality of SCD VOC care with their associated outcomes remain pronounced and present within a universal and publicly funded healthcare system.

16 September 2024
Verified
Other
Open access
PDF file
AVAna Vujovic
Ana Vujovic
LRLaura de Rooij
Laura de Rooij
ACAva Keyvani Chahi
Ava Keyvani Chahi
HCHe Tian Chen
He Tian Chen
BYBrian A. Yee
Brian A. Yee
KHKristin J. Hope
Kristin J. Hope
Supplemental Figure S3 shows the generation of the bcCML mouse model and the effects of ELAVL1 on normal bone marrow in vivo.

16 September 2024
Verified
Other
Open access
PDF file
AVAna Vujovic
Ana Vujovic
LRLaura de Rooij
Laura de Rooij
ACAva Keyvani Chahi
Ava Keyvani Chahi
HCHe Tian Chen
He Tian Chen
BYBrian A. Yee
Brian A. Yee
KHKristin J. Hope
Kristin J. Hope
Supplemental Figure S1 shows expression of RBPs in healthy HSPCs and RN2c cells, sgRNA drop out dynamics in primary and secondary transplants, the molecular functions and biological processes associated with the hit RBPs and their gene essentialities.

16 September 2024
Verified
Other
Open access
PDF file
AVAna Vujovic
Ana Vujovic
LRLaura de Rooij
Laura de Rooij
ACAva Keyvani Chahi
Ava Keyvani Chahi
HCHe Tian Chen
He Tian Chen
BYBrian A. Yee
Brian A. Yee
KHKristin J. Hope
Kristin J. Hope
Supplemental Figure S1 shows expression of RBPs in healthy HSPCs and RN2c cells, sgRNA drop out dynamics in primary and secondary transplants, the molecular functions and biological processes associated with the hit RBPs and their gene essentialities.